Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tenecteplase · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| tenecteplase | DRUG | - |
| enoxaparin | DRUG | - |
| clopidogrel | DRUG | - |
| percutaneous coronary intervention | PROCEDURE | - |
Inclusion Criteria: * Male or non-pregnant female patients aged \>18 years * Patients with symptoms presumed secondary to STEMI lasting at least 20 minutes and accompanied by ECG evidence \>2 mm of ST elevation in 2 or more contiguous precordial leads or in 2 or more limb leads;or \> 1mm ST elevati...
Tenecteplase is used for myocardial infarction, commonly known as a heart attack. It is being investigated as a treatment for this condition in a clinical trial setting. The drug is currently in Phase 2 development for this cardiovascular indication.
Tenecteplase is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's potential in treating myocardial infarction.
Tenecteplase is in Phase 2 clinical development for myocardial infarction. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied to assess its safety and efficacy in patients with this condition.
Tenecteplase is associated with one completed clinical trial, NCT00121446, titled 'Which Therapy for Acute Heart Attacks? (The WEST Study)'. This Phase 2 trial enrolled 300 participants with myocardial infarction in Canada. The study was not double-blinded and did not use a control group.
Yes, tenecteplase is classified as a small molecule therapeutic. It is being developed as a treatment for myocardial infarction, a cardiovascular condition. The drug is currently in Phase 2 clinical trials, with one completed study involving 300 patients.